Vyant Bio (NASDAQ: VYNT) Engages Skyline Corporate Communications Group, LLC To Continue Advancing Its Communications With The Financial Industry

Vyant Bio Inc. VYNT, a biotechnology company focused on identifying unique biological targets and novel and repurposed therapeutics, has retained the services of Skyline Corporate Communications Group, LLC. Skyline will manage Vyant Bio’s investor relations and corporate communications activities within the financial community.

Vyant Bio has built a platform of therapeutics to treat neurodevelopmental and neurodegenerative diseases, with current programs targeting Rett syndrome, CDKL5 deficiency disorders and Parkinson’s disease. The company’s approach to drug discovery integrates human-derived biology with artificial intelligence and machine-learning technologies to de-risk candidate selection to improve the potential effectiveness of drugs discovered earlier in the development cycle. 

Skyline Corporate Communications Group LLC, with offices in Boston and New York City, is an investor relations and corporate communications firm providing strategic messaging and investor communications consulting services for public corporations. Skyline also gives strategic assistance to companies in the financial markets and investment community by effectively communicating their corporate message and competitive advantages.

"Our recent scientific activities, clinical achievements and upcoming clinical milestones prompted Vyant Bio to select Skyline as our investor relations firm,” Vyant Bio CEO Jay Roberts said. “Vyant Bio is developing and bringing important therapeutic assets into our pipeline that we expect to enhance shareholder value. We believe that Skyline’s strong reputation, communications strategies, methodologies and standards are an excellent pairing for us as we accelerate clinical discovery and development. Skyline is a skilled partner who will work closely with us to communicate our message to the investing public.”

“We are very pleased to welcome biotechnology company Vyant Bio to our compelling and growing base of diverse clients,” Skyline President and CEO Scott Powell said. “Vyant Bio is entering an exciting scientific discovery and advancement stage, and we are delighted to provide assistance in effectively and strategically communicating this message to its existing and prospective shareholder base while broadening awareness of the company within the U.S. financial community.”

For more information about Vyant Bio LLC, visit www.vyantbio.com. 

The preceding/following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and Skyline Corporate Communications Group, LLC, a financial partner of Benzinga. This article/video is a paid sponsorship by investor relations agency Skyline Corporate Communications Group, LLC, which is paid by Vyant Bio Inc. VYNT for providing investor relations and corporate communications services relating to the Company’s securities. Please see Skyline's 17(b) Disclaimer and Disclosure Statement here: https://skylineccg.com/disclosures/. 

Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. 

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Featured photo by Shutterstock.